Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 3:2023:5386635.
doi: 10.1155/2023/5386635. eCollection 2023.

PSMA1, a Poor Prognostic Factor, Promotes Tumor Growth in Lung Squamous Cell Carcinoma

Affiliations

PSMA1, a Poor Prognostic Factor, Promotes Tumor Growth in Lung Squamous Cell Carcinoma

Zhao Liu et al. Dis Markers. .

Abstract

Lung squamous cell carcinoma (LUSC) has a poor clinical prognosis and lacks effective targeted therapy. This study is aimed at investigating the role of PSMA1 (proteasome subunit alpha type-1) in LUSC. The differential expression genes (DEGs) in LUSC were retrieved from The Cancer Genome Atlas (TCGA) by "edgR" algorithm and by "limma" R package. Then, the relationship between genes and overall survival (OS) was explored by the least absolute shrinkage and selection operator (LASSO) and multivariate Cox (multi-Cox) regression. Next, the PSMA1 expression in tissues of LUSC was detected by IHC, qRT-PCR, and western blot (WB). Moreover, the effects of PSMA1 on the proliferation and viability of LUSC cell were explored by cell counting kit 8 (CCK-8) assays, colony formation assays, and flow cytometry (FCM) analysis. All 4421 DEGs were screened by TCGA database, and 26 genes associated with OS were selected by multi-Cox. Based on TCGA database, PSMA1 was highly expressed in tissues of LUSC patients, and OS and FP of patients with PSMA1 overexpression were significantly lower than those of patients with low PSMA1 expression. Furthermore, PSMA1 knockdown significantly decreased the proliferation of LUSC cells and promoted the apoptosis of LUSC cells, and these effects were reversed by PSMA1 overexpression. The results of this project supported that PSMA1 might be a critical gene regulating the development of LUSC and has the potential to be explored as a prognostic biomarker of LUSC.

PubMed Disclaimer

Conflict of interest statement

The authors state that there are no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Differentially expressed gene in LUSC based on TCGA database. (a) Volcano plots of differentially expressed gene in the limma package based on an adj.P.Val < 0.05 and log |log FC| > 1; (b) volcano plots of differentially expressed gene in the edgR package based on FDR < 0.05 and |log FC| > 1; the red dots represent the upregulated genes; the green dots represent the downregulated genes based; the gray spots represent genes with no significant difference in expression. (c) The Venn diagram demonstrates the intersections of genes between the limma package and edgR package.
Figure 2
Figure 2
The prognostic genes in LUSC. (a) The prognostic genes extracted by univariate Cox regression analysis. (b) The trajectory of each prognosis-related candidate gene's coefficient in diffuse-type LUSC was observed in the LASSO coefficient profiles with the changing of the lambda in LASSO algorithm. (c) After the 10-fold cross-validation, a confidence interval was obtained for partial likelihood deviance as the lambda changed. (d) The prognostic genes related with OS extracted by multi-Cox regression analysis.
Figure 3
Figure 3
The survival analysis of PSMA1 with LUSC. (a, b) The expression of PSMA1 in tissues from patients with LUSC: (a) TIMER database and (b) UALCAN database. (c, d) The survival analysis of PSMA1 in tissues from patients with LUSC: (c) OS and (d) FP.
Figure 4
Figure 4
Analysis of PSMA1 level in cells. (a) The mRNA expression of PSMA1 in tissues of LUSC patients was detected by qRT-PCR. (b) Protein expression of PSMA1 was detected by WB in tissues from patients with LUSC. (c) IHC staining for PSMA1 in tissues of LUSC patients. (d) Quantitative RT-PCR analysis of PSMA1 in LTEP-s, NCI-H596, and NCI-H520 cells. (e) Western blot analysis of PSMA1 in LTEP-s, NCI-H596, and NCI-H520 cells. PSMA1 molecular weight: 84 kDa.
Figure 5
Figure 5
The study of the mechanism of PSMA1 in the cell. (a) The protein expression of PSMA1 was analyzed in PSMA1-depleted cells and PSMA1-overexpressed cells by western blot (right) analyses. (b) The viability cell was detected by CCK-8 when PSMA1 was sliced and PSMA1 was overexpressed. The cells were measured at 24, 48, 72, and 96 h. (c) Clone formation assay showing the proliferation ability of the LTEP-s and NCI-H596 cells with the vector-PSMA1 group and shPSMA1-1# and shPSMA1-2# compared with the vector-empty group and shNC group, respectively. (d) Cell apoptosis distribution was determined by flow cytometric analysis in LTEP-s and NCI-H596 cells in the vector-PSMA1 group and shPSMA1-1# and shPSMA1-2# compared with the vector-empty group and shNC group.

Similar articles

Cited by

References

    1. Zhuang Y., Li S., Liu C., Li G. Identification of an individualized immune-related prognostic risk score in lung squamous cell cancer. Frontiers in Oncology . 2021;11, article 546455 doi: 10.3389/fonc.2021.546455. - DOI - PMC - PubMed
    1. Xia L., Yu Y., Lan F., et al. Case report: tumor microenvironment characteristics in a patient with HER2 mutant lung squamous cell carcinoma harboring high PD-L1 expression who presented hyperprogressive disease. Frontiers in Oncology . 2021;11, article 760703 doi: 10.3389/fonc.2021.760703. - DOI - PMC - PubMed
    1. Jiang T., Chen J., Xu X., et al. On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial. Molecular Cancer . 2022;21(1):p. 4. doi: 10.1186/s12943-021-01479-4. - DOI - PMC - PubMed
    1. Yan D., Chen Y. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients. Scientific Reports . 2021;11(1):p. 9020. doi: 10.1038/s41598-021-88694-7. - DOI - PMC - PubMed
    1. Friedlaender A., Banna G., Malapelle U., Pisapia P., Addeo A. Next generation sequencing and genetic alterations in squamous cell lung carcinoma: where are we today? Frontiers in Oncology . 2019;9:p. 166. doi: 10.3389/fonc.2019.00166. - DOI - PMC - PubMed

Substances